Combinatorial chemoprevention of intestinal neoplasia

Area of Science:

• Oncology
• Gastroenterology
• Pharmacology

Background:

• Familial adenomatous polyposis (FAP) is a hereditary condition characterized by numerous precancerous intestinal polyps.
• APC(Min/+) mice serve as a valuable model for studying FAP and evaluating potential chemopreventive agents.
• Non-steroidal anti-inflammatory drugs (NSAIDs) like sulindac have shown promise in cancer chemoprevention.

Purpose of the Study:

• To investigate the combined efficacy of sulindac and EKI-569 in preventing intestinal neoplasia.
• To evaluate the chemopreventive potential of targeting both inflammation and epidermal growth factor receptor (EGFR) signaling in FAP.

Main Methods:

• Treatment of APC(Min/+) mice with a combination of sulindac and EKI-569.
• Assessment of polyp formation and burden in treated versus untreated control groups.
• EKI-569 was used as an irreversible inhibitor of the epidermal growth factor receptor kinase.

Main Results:

• Untreated APC(Min/+) mice developed an average of 20 intestinal polyps.
• Nearly 50% of mice treated with the combination of sulindac and EKI-569 developed no polyps.
• The combination therapy demonstrated remarkable protection against intestinal neoplasia.

Conclusions:

• The combination of sulindac and EKI-569 is a highly effective strategy for preventing intestinal polyps in a murine model of FAP.
• This dual-drug approach holds significant potential for the chemoprevention of human colonic neoplasia.
• Targeting inflammatory pathways and EGFR signaling concurrently may offer a powerful therapeutic strategy for FAP.